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Abstract

Introduction

Recently, considerable progress has been made in
designing biomaterial surfaces which possess enhanced
albumin affinity. Two derivatization methods for producing albumin binding biomaterial surfaces, based on
an albumin affinity dye, cibacron blue, have been developed. Both surface derivatization methods were found
to enhance the binding of albumin to an implant grade
polyetherurethane. Evaluations of the enhanced albumin
affinity demonstrated the binding to be both selective
and reversible. Surfaces having such enhanced albumin
affinity were found to be minimally thrombogenic and to
discourage the adhesion of bacteria which might otherwise cause device-centered infections. We conclude that
albumin affinity surfaces, such as these, may be useful
in the design of non-thrombogenic and infection resistant
biomaterials.

Thrombosis is a major complication affecting polymeric blood-contacting medical devices (Lindsay, 1980;
Leininger et al., 1987). These devices tend to be
thrombogenic due, in part, to the surface adsorption of
a variety of plasma proteins which can initiate coagulation and activate platelets (Zucker and Vroman, 1969;
Kim et al., 1974; Absolom et al. , 1987; Collins et al.,
1987; Fukumura et al., 1987; Salzman et al. , 1987;
Sevastianov, 1988; Ito and Imanishi, 1989). This procoagulant activity of many polymeric devices prevents
their use in vi vo or greatly diminishes their useful lifetime. Besides being procoagulant, these same devices
can also serve as foci for infection, promoted by the
tendency of certain microorganisms to adhere to, and
colonize, their surfaces (Christensen et al., 1982; Lowy
and Hammer, 1983; Gower et al., 1986; Hogt et al.,
1986, 1987; Schmitt et al., 1986; Jansen et al., 1989).
For these reasons, there is a real medical need to create
polymeric materials which are less thrombogenic and
less liable to harbor pathogenic bacteria.
One potential solution to the problem of surface adsorption of procoagulant proteins and cells on polymeric
materials is based on the selective adsorption of albumin. Indeed, in some experimental systems, surfaces
coated directly with albumin have demonstrated diminished adherence of cells and, especially, platelets (Zuckerand Vroman, 1969; Kimetal., 1974; Absolometal.,
1987). Unfortunately, thus far, there has been no fully
effective way of creating polymeric materials with surfaces which selectively bind albumin in vivo.
One prior promising attempt was based on the wellknown ability of albumin to bind free fatty acids; surfaces displaying straight-chain 16- or 18-carbon alkyl
groups were made in hopes that this might enhance surface albumin affinity (Munro et al., 1981). Indeed, the
addition of alkyl chains did increase the surface affinity
for albumin during brief incubations (Frautschi et al.,
1983; Eberhart et al., 1987; Pitt and Cooper, 1988) and
improved thromboresistance in an acute canine ex vivo
experiment (Grasel et al., 1987). However, these
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pellets, an implant grade polyetherurethane, was added.
The resultant mixture was then shaken overnight to allow complete solvation of the polyurethane. The solvated blue dextran/polyurethane mixture was then cast
into film (0.3 mm thick) on Mylar® (Custom Coating
and Laminating Corporation, Worcester, MA) release
sheets or tubing (2 mm internal diameter, ID) on glass
mandrels and dried overnight in a vacuum oven at 50°C
to remove the solvent.
The covalent attachment of blue dextran to the surface of the polyurethane also has been previously described (Keogh and Eaton, 1994). Briefly, raw pelletized 55D was extruded into film (0.3 nun thick) using a
RC 0625 Randcastle (Little Falls, NJ) vertical screw extruder and into tubing (2 nun ID) using a Harrel (Norwalk, CT) horizontal screw extruder. No processing
aids were added prior to extrusion. The film was then
cut into 1 cm2 sample disks. Both tubing and sample
disks were cleansed in reagent grade ethanol (Sigma) for
at least two hours to remove most surface contamination,
thoroughly rinsed in DI water and allowed to dry. Extruded 55D samples were then placed into a surface
grafting solution consisting of 11.2 M acrylamide
(AAm) (Eastman Kodak Co., Rochester, NY), 1.1 M
N-(3-aminopropyl)methacrylamide (APMA) (Eastman
Kodak), 400 mM nitric acid (HN0 3) (Aldrich Chemical
Co., Milwaukee, WI) and 40 mM ammonium cerium
(IV) nitrate [(NH4hCe(N0 3) 6] (Aldrich) in DI water.
Grafting was allowed to proceed for 30 minutes before
the samples were removed and thoroughly rinsed in DI
water to remove any residual monomer.
Sodium metaperiodate (Nal0 4) (Sigma) oxidized
dextran (Sigma), 2 million molecular weight, was then
coupled through Schiffs base formation to the AArn!
APMA grafted polyurethane surface. Dextran was oxidized by placing 5.0 g of dextran in 100 ml DI water
containing 5.0 mg Nal0 4 , incubating in the dark for 2
hours and then dialyzing against DI water for 24 hours
to remove any residual periodate. The AAm/ APMAgrafted polyurethane was placed in the oxidized dextran
solution at 25°C and stirred. After 1 hour, 3 mg/ml
sodium cyanoborohydride (NaCNBH3) (Sigma) was
added, and the samples were incubated with stirring for
2 hours at 25°C, thus stabilizing the Schiffs bases
which had formed between the aldehydes of oxidized
dextran and the amino groups of APMA. The samples
were then removed and rinsed thoroughly in DI water.
Cibacron blue 3GA dye (Sigma) was then covalently
coupled to the AAm/ APMA-dextran derivatized polyurethane by incubating the derivatized polyurethane for 6
hours in a dye solution containing 6.5 mM cibacron blue
dye, 0.3 M NaCl (Sigma) and 0.7 M NaHC03 (Sigma)
in DI water. The blue dextran surface-derivatized polyurethane was then rinsed thoroughly in DI water.

materials are not entirely selective for albumin binding
and may, due to the highly hydrophobic nature of the
surface, encourage the subsequent denaturation of
adsorbed protein (Andrade and Hlady, 1986).
Our attempt to engineer polymeric surfaces with enhanced albumin affinity is based on the ability of albumin to bind a variety of triazine dyes such as cibacron
blue. In fact, a commonly used technique for purifying
albumin relies on this afftnity. The purification technique involves the passage of solutions containing albumin, e.g., plasma, over an affinity support matrix to
which cibacron blue dye is covalently bound (Travis et
al. , 1976). A variety of affmity support matrices including agarose (Sigma Chern. Co., St. Louis, MO),
Sephacryl® (Sigma), Sephadex (Sigma), Sepharose
(Sigma), etc. have been used (Kopperschlager et al.,
1982). In our work, we have used a 2 million molecular weight dextran . We felt that dextran would act as an
appropriate hydrophilic "spacer," thus preventing the
close surface approach and consequent denaturation of
bound albumin. We also anticipated that the dextran
spacer would be highly stable in vivo due to the fact that
mammals lack dextranase enzymes. Furthermore, cibacron blue dye is quite stable at extreme pHs. Therefore,
although the catabolism of this dye in vivo has not been
characterized, we felt that it would likely resist degradation . We also predicted that polymeric materials displaying "blue dextran" (dextran coupled with cibacron
blue dye) would spontaneously, selectively and reversibly bind albumin upon contact with blood and certain
other body fluids. With this in mind , two methods were
developed to incorporate blue dextran on the surface of
polymeric materials. (1) The first employs a co-solvation technique for incorporating blue dextran throughout
a polyurethane. (2) The second method covalently
attaches blue dextran to the surface of the polyurethane.
The resultant polymeric materials from both derivatization methods demonstrate an increase in albumin affinity. This increase in albumin affinity confers a number
of desirable properties, including increased thromboresistance and decreased bacterial adherence.

Materials and Methods
Incorporation of blue dextran
The co-solvation technique for incorporating blue
dextran throughout a polyurethane has previously been
described (Keogh et al., 1992). Briefly, 0.3 g of blue
dextran (BD) (Sigma Chemical Co., St. Louis, MO) was
dissolved in 1.5 m1 of deionized (Dl) water. This mixture was then added to 20 g of N,N-dimethylacetamide
(DMAC) (Fisher Scientific Co., Pittsburg, PA). To this
blue dextran/solvent mixture, 1.0 g of raw 2363-55D
(55D) Pellethane (Dow Chemical Co., Midland, Ml)
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Surface characterization

decyl sulfate (SDS) are considered denatured and irreversibly bound (Bohnert and Horbett, 1986; Rapoza and
Horbett, 1989; Chinn et al. , 1991, 1992). Therefore,
the reversibility of albumin binding to blue dextranderivatized surfaces was determined by measuring the
elutability of previously adsorbed protein using a 1%
SDS (Sigma) wash. Disks of bulk-derivatized, surfacederivatized and non-derivatized 55D were incubated for
5 hours in 1251-labeled albumin (15.7 J.tg/ml) at 25°C.
The samples were then rinsed with PBS and incubated in
PBS alone or in a 1% SDS solution for 1 hour at 25°C.
After incubation, the samples were rinsed in PBS,
placed in scintillant and counted in a scintillation
counter.
Reversibility of albumin binding was also estimated
by the release of 125 1-labeled albumin by subsequent incubation in solutions of unlabeled albumin. Again, bulkderivatized, surface-derivatized and non-derivatized 55D
disks were incubated for 5 hours in 125 !-labeled albumin
(15.7 J.tglml) at 25°C. The samples were then rinsed in
PBS followed by immersion in PBS containing 1 mg/ml
unlabeled human serum albumin for 1 hour at 25°C.
The extent of displacement of bound 125 1-labeled albumin by free unlabeled albumin was then determined by
scintillation counting of both disks and supernatants.
Finally, the extent to which surface binding of albumin by blue dextran-derivatized polyurethane is mediated
specifically by an association between the immobilized
cibacron blue dye and albumin was determined by using
solution-phase blue dextran to competitively elute bound
albumin. Bulk-derivatized, surface-derivatized and nonderivatized 55D disks were incubated in 1251-labeled
albumin (15.7 J.tg/ml) for 5 hours at 25°C. The samples
were then rinsed in PBS and incubated in PBS alone or
in PBS containing soluble blue dextran (5 mg/ml) for 1
hour at 25°C. Following incubation, the samples were
rinsed in PBS, placed in scintillant and counted in a
scintillation counter.

The extent of blue dextran derivatization on polyurethane surfaces was assessed with several techniques.
Fourier transform infrared spectroscopy with attenuated
total reflectance optics (FTIR/ ATR) was performed with
a SPC 3200 Bio-Rad (Cambridge, MA) spectrometer
and a 45° germanium ATR crystal. Electron spectroscopy for chemical analysis (ESCA) was performed on
material surfaces using a 5400 Perkin-Elmer Physical
Electronics (Eden Prairie, MN) ESCA spectrometer.
Scanning electron microscopy (SEM) was performed on
material surfaces following mounting and sputter-coating
with gold. The samples were viewed using a JSM-35CF
JEOL (Peabody, MA) SEM.

Albumin affinity detenninations
The extent of surface binding of albumin to blue
dextran bulk-derivatized 55D sample disks (1 cm2 )
(hereafter, "bulk-derivatized 55D") and blue dextran
surface-derivatized 55D sample disks (1 cm2 ) (hereafter,
"surface-derivatized 55D") was estimated by incubation
of derivatized samples in solutions containing radiolabeled human albumin. Sample disks ofbulk-derivatized,
surface-derivatized and non-derivatized 55D were first
rinsed in isotonic phosphate buffered saline (PBS), pH
7 .4, at 25°C for 15 minutes prior to incubation for 1
hour at 25°C in 125 1-labeled human albumin diluted in
PBS (final concentration = 15.7 J.tg/ml; specific activity
= 8.5 14Ci/mg protein) (Mallinkrodt, St. Louis, MO).
Following incubation, the samples were thoroughly
rinsed with PBS, placed in scintillant and then counted
in a scintillation counter.
The selectivity of the binding of albumin by bulkderivatized, surface-derivatized and non-derivatized 55D
in the presence of 125 1-labeled fibrinogen (15. 7 J.tg/ml;
specific activity = 115 14Ci/mg protein) (Amersham, Arlington Heights, IL) was determined using 1: 1 mixtures
of albumin and fibrinogen . Fibrinogen was used as a
competitive protein since it is well known that fibrinogen
readily adsorbs to most medical device surfaces and because surfaces with adsorbed fibrinogen tend to be
thrombogenic (Zucker and Vroman, 1969; Kim and Lee,
1979; Chinn et al., 1991). Disks of bulk-derivatized,
surface-derivatized and non-derivatized 55D were exposed to a 1:1 by weight 125 1-labeled albumin/unlabeled
fibrinogen or 1251-labeled fibrinogen/unlabeled albumin
mixture (final protein concentration, 15.7 J.tg/ml) for 1
hour at 25°C. In making these mixtures, the albumin
added to 1251-labeled fibrinogen by the supplier was
taken into account. The samples were then thoroughly
rinsed with PBS, placed in scintillant and counted in a
scintillation counter.
Proteins that remain adherent to the surface of polymeric materials despite thorough washing in sodium do-

Thromboresistance measurements
As one indication of the tendency of blue dextranderivatized polyurethane to affect clotting of whole
blood, limited studies using a Baumgartner (1973) apparatus and a Chandler (1958) blood loop were performed.
For investigations using the Baumgartner apparatus, venous blood was drawn from a human subject (who had
not taken aspirin within the last two weeks) into a plastic
vessel containing citrate. These studies were approved
by the Committee on Research Involving Human Subjects, University of Minnesota. The citrate-anticoagulated blood, maintained at 3rc, was then pumped
through the Baumgartner (1973) perfusion chamber containing bulk-derivatized and non-derivatized 55D tubing
samples (2 mm ID and 5 em in length). Blood flow was
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maintained at a rate of 140 ml/min (shear rate of 800
s- 1) for five minutes. The samples were then removed,
fixed and stained with Diff-Quik (Baxter Healthcare
Corp., McGraw Park, IL) stain set. Adherent platelets
were quantified using a light microscope (field size of
3.7 X 10-J mm2).
For investigations using a Chandler (1958) blood
loop, venous blood was again drawn from a human subject into a plastic syringe containing no anticoagulant.
One-milliliter aliquots of whole human blood were then
delivered immediately into (1) a 12 mm x 75 mm glass
test tube, (2) an ethanol-sterilized non-derivatized 550
tubing sample (2 mm ID and 30 em in length) and (3) an
ethanol-sterilized surface-derivatized 55D tubing sample
(also 2 mm ID and 30 em in length). One end of each
of the polyurethane tubes was looped around and connected to the other end via an external silicone sleeve.
The 1 m1 aliquot of whole blood was purposely not
enough blood to fill the entire tube, thus forming an airblood interface which tends to accelerate the clotting of
whole blood. The polyurethane tubes were then attached
to a vertical circular plate and rotated at 9 rpm at 37 o C
until the blood clotted. The glass test tube was gently
tilted every 30 seconds at 37°C until the blood clotted.
After 16 hours (the long incubation due to the fact
that the blood within the surface-derivatized 55D tubing
samples never clotted), the blood was expelled from the
sample loops. The tubing samples were then vigorously
rinsed in PBS and placed in 2.5% glutaraldehyde (Sigma) solution overnight. Following mounting and sputter-coating with gold, sample surfaces were examined
with a JEOL JSM-35CF SEM for adherent thrombus.
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Figure 1. Adsorption of 1251-labeled human albumin on
non-derivatized 55D, bulk-derivatized 55D and surfacederivatized 55D disks. Quadruplicate samples were incubated in 125 I-labeled albumin (15.7 1-1-g/ml) for 1 hour
at 25°C and thoroughly rinsed in PBS. The surface associated 125!-labeled albumin was determined by scintillation counting. Results are expressed as the mean total
amount of albumin adsorbed/cm2 ± 1 standard deviation , SD (p < 0.01 between non-derivatized and both
derivatized samples, Student's t-test, two-tailed).

solution and placed in 5 m1 of sterile saline solution .
The samples were then gently sonicated at 20 W for 1
minute to release adherent bacteria. This power setting
was experimentally determined not to decrease the viability of solution-phaseS. epidermidis. After sonication,
the numbers of displaced bacteria were enumerated by
pour-plating appropriate dilutions as previously described
(Ma and Eaton, 1992).

Bacterial adherence assay
Bacterial adherence to implant surfaces is thought to
be a major mechanism underlying the high frequency of
device-associated infections. We, therefore, carried out
limited bacterial adherence studies with bulk-derivatized,
surface-derivatized and non-derivatized 55D samples
using Staphylococcus (S.) epidermidis. S. epidermidis
(an uncatalogued "slime"-producing clinical isolate obtained from an infected catheter by the Microbiology
Laboratory at the University of Minnesota) were grown
overnight in Brain Heart Infusion broth (Difco Co., Detroit, MI) in a shaking water bath at 37°C. The bacteria
were then concentrated centrifugally and washed three
times in isotonic saline solution and resuspended in sterile Hanks' balanced salt solution to 1.05 x 109 cfu/ml.
Bulk-derivatized, surface-derivatized and non-derivatized
55D sample disks (1.0 cm 2), both with and without
preadsorption of albumin (15. 7 J.Lg!ml) for 4 hours at
25°C, were immersed in this bacterial suspension with
gentle mixing for 1 hour at 25°C. After incubation, the
samples were thoroughly rinsed in sterile isotonic saline

Results
Surface characterization
As reported earlier (Keogh, 1992; Keogh and Eaton,
1994), the blue dextran bulk derivatization technique
partially obscured the polyurethane surface as estimated
with FTIR/ ATR and ESCA. In contrast, the blue dextran surface derivatization technique completely obscured
the polyurethane surface as estimated with FTIR/ ATR
and ESCA, and the resultant surface coating had a thickness of approximately 2 ~-tm. as estimated with SEM.
Albumin affinity
Blue dextran surface-derivatized 55D was found to
bind approximately twice as much 125 1-labeled albumin
as did non-derivatized 55D and roughly 50% more than
bulk-derivatized 55D (Fig. 1). This enhanced albumin
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Table 1. The number of platelets spontaneously adherent to non-derivatized 55D tubing and bulk-derivatized
55D tubing. Triplicate samples were placed in a Baumgartner apparatus and exposed to flowing citrate-anticoagulated whole human blood for 5 minutes at 37°C.
Adherent platelets were quantified using light microscopy. Results are expressed as the mean number of
platelets/mm2 ± 1 SD (20 fields of size 3. 7 X w-3 mm2 ;
non-derivatized differs from bulk-derivatized 55D at
p < 0.01, Student's t-test, two-tailed).

non-derivatized 55D
bulk-derivatized 55D

surface

Figure 3. Percent elution of albumin previously bound
to non-derivatized 55D, bulk-derivatized 55D and surface-derivatized 55D disks by SDS, albumin or solutionphase blue dextran . Triplicate samples were incubated
in 125 1-labeled albumin (15.7 J.tglrnl) for 5 hours at 25°C
and thoroughly rinsed in PBS. The samples were then
incubated for 1 hour at 25°C in a 1% SDS solution, a
solution of 1 mg/rnl soluble unlabeled albumin or a solution of 5 mg/ml soluble blue dextran . The surface associated 125!-labeled albumin was determined by scintillation counting. Results are expressed as the mean percentage of elutable albumin ± 1 SD (p < 0.01 non-derivatized or both types of derivatized samples, Student's
t-test, two-tailed).

Figure 2. Relative adsorption of albumin and fibrinogen
to non-derivatized 55D , bulk-derivatized 55D and surface-derivatized 55D disks. Triplicate samples were incubated in either a 1:1 by weight 125 I-labeled albumin/fibrinogen or 125 I-labeled fibrinogen/albumin mixture (fmal protein concentration, 15.7 J.tg/rnl) for 1 hour
at 25°C and thoroughly rinsed in PBS. The surface associated 1251-labeled albumin or 1251-labeled fibrinogen
was determined by scintillation counting. Results are
expressed as the mean percentage of total protein
adsorbed ± 1 SD.

Sample

bulk

Table 2. Times at which 1 rnl of freshly shed whole
human blood clotted in non-derivatized 55D tubing, surface-derivatized 55D tubing and glass test tubes. Results
shown are from a single experiment involving duplicate
samples. These results are representative of three additional and independent experiments (all four blood samples from a single donor). Overall, for glass and nonderivatized SSD, the time at which clotting occurred
varied by no more than 10%.

# Platelets/mm2
23,000 ± 8,700
81 ± 154

binding appears to be selective. As shown in Figure 2,
when non-derivatized 55D is incubated with equal
proportions (weight/weight) of fibrinogen and albumin,
bound fibrinogen predominates.
However, similar
experiments with blue dextran-derivatized surfaces
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Sample

Clotting Time

glass test tube

5.75 minutes

non-derivatized 55D

9.5 minutes

surface-derivatized 55D

> 16 hours
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Figure 4. Light micrographs of the surfaces of (A) nonderivatized 55D and (B) bulk-derivatized 55D after a 5
minute exposure to flowing citrate-anticoagulated human
blood at 3rc. Bars = 10 J.'m.
Figure 5. Scanning electron micrographs of the surfaces of (A) non-derivatized 55D and (B) surface-derivatized 55D after a 16 hour exposure to flowing non-anticoagulated human blood at 37°C. Bars = 10 J.'ffi.

reveale.d an albumin preference of almost 70% in the
case of bulk-derivatized 55D, and over 95% in the case
of surface-derivatized 55 D. Furthermore, less than 30%
of the albumin bound to non-derivatized 55D was elutable by SDS, solution-phase blue dextran or albumin
(Fig. 3). However, albumin binding to blue dextran-derivatized surfaces was found to be much more reversible
and ligand specific. As shown in Figure 3, at least 70%
of the albumin which binds to bulk-derivatized 55D is
released by SDS and appears to be ligand specific (i.e.,

is released by solution phase albumin and blue dextran).
In the case of surface-derivatized 55D, more than 95%
of the bound albumin appears to be bound reversibly to
the surface incorporated blue dextran.
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Figure 7. Bacterial adherence to albumin-coated nonderivatized 55D, bulk-derivatized 55D and surface-derivatized 55D disks. Triplicate samples were pre-incubated in albumin (15. 7 J.'g/rnl) for 4 hours at 25°C. The
samples were then incubated in a suspension of S. epidermidis solution for 1 hour at 25°C. After incubation
in the bacterial suspension, the samples were rinsed and
sonicated. The bacteria displaced were then plated, incubated and counted. Results are expressed as the mean
number of cfu/cm2 ± 1 SD (p < 0.01 between all samples, Student's t-test, two-tailed).

The results in Table 2 indicate that surface-derivatized 55D also has a profound inhibitory effect on the
clotting of whole blood. In fact, non-anticoagulated venous blood clotted within 6 minutes in glass tubes, within 9 to 11 minutes in non-derivatized 55D tubes, but did
not clot even after 16 hours incubation in surface-derivatized 55D tubing. Scanning electron micrographs of the
tubing from the incubations reported in Table 2 revealed
multiple thrombi and fibrin strands on the surface of the
non-derivatized 55D (Fig. SA). In contrast, there was
little or no cellular adhesion of any kind on the surfacederivatized 55D (Fig. 5B). Note that the rugosities evident on the surface-derivatized 55D represent, in part,
a drying artifact which may reveal areas of primary "nucleation" of the eerie ion grafting of acrylamide to the
surface of the polyurethane. These nucleation sites are
more clearly evident when comparing clean surfaces of
non-derivatized 55D (Fig. 6A) and surface-derivatized
55D (Fig. 6B).

Figure 6. Scanning electron micrographs of surfaces of
(A) non-derivatized 55D and (B) surface-derivatized
55D. Bars = 2 J.tm.
Thromboresistance
When tubing samples were studied under flow in a
Baumgartner (1973) device, large numbers of platelets
were found to adhere to non-derivatized 55D, whereas
almost no detectable platelets were adherent to bulk-derivatized 55D (Table 1). Importantly, the large numbers
of platelets adherent to non-derivatized 55D were activated, as indicated by the spread pseudopodia of adherent platelets (Fig. 4A). In contrast, the few platelets
found on bulk-derivatized 55D were not activated by
morphological criteria (Fig. 4B).

Bacterial adherence
Finally, as shown in Figure 7, the binding of S.
epidermidis to bulk-derivatized 55D surfaces is more
than 70% less than that to non-derivatized 55D surfaces
when the surfaces were pre-incubated with albumin.
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tenaciously (Kd - w- 7 , dissociation constant derived
from Scatchard plot) to immobilized cibacron blue dye
(perhaps through a specific interaction with the bilirubin
binding site on albumin) (Leatherbarrow and Dean,
1980). While other proteins and, especially, adenine nucleotide-dependent enzymes also bind to immobilized cibacron blue dye, albumin is by far the predominant plasma protein which binds this dye (Travis et al., 1976).
Based on cibacron blue dye, two derivatization
methods for producing albumin affinity biomaterial surfaces were developed. Evaluations of albumin affmity
of polymeric materials incorporated with cibacron blue
dye demonstrate that both methods produce surfaces
which preferentially bind albumin even from mixtures
containing equal amounts of both fibrinogen and albumin. Furthermore, albumin is bound to these surfaces
by a ligand-affinity mechanism in as much as previously
bound albumin is readily released by solution-phase albumin or blue dextran. In addition, these cibacron blue
derivatized materials have an unexpectedly potent antithrombogenic character, retarding non-cellular clotting
as well as platelet adherence. Finally, these hydrophilic
albumin affinity surfaces discourage the adherence of potentially pathogenic bacteria. We conclude that surfaces
with similar characteristics may hold some promise for
the development of less thrombogenic biomaterials which
also are less liable to foster device-associated infections
by adherent microorganisms.

More strikingly, however, bacteria are almost completely incapable of adhering to the surfaces of surface-derivatized SSD which has been pre-incubated with albumin.

Discussion
Thrombosis and infection are among the most frequent iatrogenic problems associated with implantable
and blood-contact medical devices. Especially in the
case of devices made of polymeric elastomers, these adverse effects may be initiated by rapid formation of a
layer of adsorbed, apparently denatured, proteins on the
surface. This chaotic array of adsorbed proteins may be
thrombogenic. Furthermore, the adsorption of fibrinogen in particular has recently been shown responsible for
the acute inflammatory effects of at least one type of implanted biomaterial (Tang and Eaton, 1993; Tang et al.,
1996). Finally, this layer of denatured host proteins
may form a substratum, permitting the adherence and
colonization of device surfaces by microorganisms.
One technique for preventing the chaotic adsorption
of proteins and cells on medical device surfaces is by
way of an albumin coating. Numerous investigators
have found that coating of a biomaterial surface with
albumin "passivates" the surface by diminishing thrombosis, the adherence of pathogenic bacteria and, perhaps,
the inflammatory response. Unfortunately, despite the
fact that albumin is the predominant plasma protein,
many other proteins typically have at least an equal
affinity to the medical device surface. Therefore, selective coating of a medical device surface with albumin
typically does not occur in vivo. Furthermore, direct
attachment of albumin to the device surface can contribute to the aforementioned problems since irreversibly
bound albumin eventually degrades. For these reasons,
there have been some attempts to engineer medical device surfaces with enhanced albumin affinity. As described earlier, one strategy was based on the wellknown ability of albumin to bind free fatty acids with
high affinity. Unfortunately, these materials are not entirely selective for albumin binding and may, due to the
highly hydrophobic nature of the surface, even encourage the denaturation of adsorbed protein.
Our work has been based on the premise that the
development of effective and compatible blood-contact
devices depends on creating surfaces which can regulate,
without denaturing, the types and amounts of protein that
adsorb on the surface. Therefore, we employed the concept of affinity chromatography to produce biomaterial
surfaces which selectively and reversibly bind albumin
in vivo. One very effective affinity chromatography
technique widely used for separating albumin from plasma involves the use of cibacron blue dye (Travis et al.,
1976). In fact, albumin from most mammals will bind
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blue dextran-derivatized surfaces?
Authors: We are confident that our radiolabeled protein
solutions contained little or no free iodide since inclusion
of large amounts of unlabeled Nal failed to change the
amounts of surface associated 1251-labeled albumin or
125 1-labeled fibrinogen found adherent to derivatized or
non-derivatized surfaces.

Discussion with Reviewers
C. Tsai: How long will the blue dextran last on the
surface?
Authors: As stated in the text, we felt the dextran
spacer would be highly stable in vivo due to the fact that
mammals lack dextranase enzymes. Also, since cibacron blue dye is quite stable at extreme pHs and, although the catabolism of this dye in vivo has not been
characterized, we felt it would likely resist degradation.
However, we have not carried out any long term implantation studies to directly measure the time.

C. Tsai: In your Chandler (1958) loop study, blue dextran surface-derivatized tubing showed no clotting phenomena (Table 2). Could you elaborate on this?
Authors: At present, we have no firm explanation for
the anti-thrombogenic activities of these surfaces. However, as shown previously (Keogh and Eaton, 1994), the
blue dextran surface may activate antithrombin III in a
heparin-like fashion. If so, this may be sufficient to
explain the long-term anticoagulant effects which we
have found .

C. Tsai: Do other plasma proteins, such as lgG, high
molecular weight Kininogen (HMWK), Factor XII and
complement proteins, which all can have a negative impact on blood compatibility of foreign materials, bind to
your surfaces?
Authors: Unfortunately, the binding of purified plasma
proteins such as lgG, HMWK, Factor XII and complement proteins has not been characterized. However, we
earlier demonstrated that wher. blue dextran surfacederivatized material was directly immersed in whole
human plasma, very few other proteins aside from albumin could be detected electrophoretically following elution from the material surface (Keogh and Eaton, 1994).
We also previously demonstrated the ability of blue dextran bulk-derivatized material to selectively bind 1251labeled albumin in the presence of increasing amounts of
albumin-depleted human serum (Keogh et al., 1992).

S.L. Goodman: Do you have any evidence on how
well the blue dextran modified surfaces maintain their
albumin binding affinity when in actual use? Does the
blue dextran detach , degrade, or otherwise lose activity
over time? If so, is there any toxicity or other problems
associated with circulating or soluble blue dextran?
Authors: Our best response to the durability question
is that we do not know. As indicated above, we have
not done the requisite long-term implantation or blood
contact studies. However, we do suspect that the blue
dextran will be relatively stable, even compared to heparin-derivatized surfaces which can potentially be attacked by heparinases known to be present in mammals.
We believe the toxicity of blue dextran is unknown.
S.L. Goodman: Do you have any direct measurements
of the concentration of blue dextran which is on the
derivatized surfaces, that is, other than the albumin
adsorption measurements? If so, how does the surface
concentration of blue dextran compare to the concentration of adsorbed albumin? Might the surface concentration of blue dextran be further optimized for reducing
thrombogenicity and bacterial adherence?
Authors: We have not yet attempted to measure the actual concentration of blue dextran which is on the derivatized surfaces. However, we do believe that the surface concentration of blue dextran or cibacron blue dye
might be further optimized for reducing thrombogenicity
and/or bacterial adherence.

C. Tsai: Since dextran contains many hydroxyl (-OH)
groups, have you performed any complement activation
tests for blue dextran-derivatized surfaces?
Authors: No formal tests have been performed for
assessing complement activation.
C. Tsai: Have you looked into any other index for
measuring platelet activation such as thromboxane B2 or
PF4 since the lack of platelet adhesion does not necessarily mean the lack of platelet activation?
Authors: It is absolutely correct that platelet adherence
alone does not prove that platelets were not being activated. We have not yet carried out studies which measure platelet activation directly.

J.A. Chinn: Does blue dextran modification of polyurethanes affect their mechanical properties?
Authors: As we reported (Keogh and Eaton, 1994), we
saw no affect on the mechanical properties of blue
dextran modified polyurethane.

C. Tsai: In your radiolabeled protein adsorption studies, what were the percentages of free iodide (i.e., labeling efficiency) in the 1251-labeled albumin and 125 1-labeled fibrinogen solutions and will free iodide adsorb to
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Authors: Once again, elution of pre-bound 125!-labeled
albumin by solution phase unlabeled albumin and by
solution phase blue dextran clearly indicates ligand
binding. Furthermore, adsorbed albumin is not displaced by dextran alone or proteins other than albumin.

J.A. Chinn: Is blue dextran modified polyurethane
chemically stable?
Do samples contain leachable
materials?
Authors: The modified samples we tested did not appear to leach any material and, as mentioned above, we
currently do not know the chemical in vivo stability of
blue dextran modified polyurethane materials.

J.A. Chinn: Was elutability of fibrinogen measured?
If fibrinogen and HSA were equally elutable, would that
result effect your interpretation of the HSA binding
data?
Authors: Fibrinogen is elutable. However, this does
not affect interpretation of our results but reflects the
fact that hydrophilic surfaces, regardless of the functionali ties exposed, do not encourage the irreversible hydrophobic denaturation of bound proteins.

J.A. Chinn: What affect did incubation of test samples
with ethanol have on mechanical as well as surface properties of this material? Was material extracted from the
polymer during incubation with ethanol, and, if so, how
did this affect your results?
Authors: We have not observed any significant effect
of ethanol rinsing on the mechanical properties of the
polyurethane materials. Depending on the length of extraction, we sometimes observe some extracted material
which we currently have not characterized. However,
we believe the extracted material to be either processing
aids Dow Chemical Co. may have added, low molecular
weight urethane or possibly a combination of both.

J.A. Chinn: How do you explain the low retention of
albumin by modified polyurethane given a Kd = w- 7?
Authors: We are not sure what you mean by low retention. It seems to us that retention of -1 monolayer after vigorous washing is pretty good. Incidentally, the
Kd probably refers to non-cooperative binding of cibacron blue by albumin, whereas it is quite possible that in
the case of polymeric cibacron blue on dextran, the
binding is cooperative.

J.A. Chinn: It appears from Figure 6B that modified
sub trate is very rough . How did surface roughness affect your results? Did you account for the increase in
surface area relative to unmodified polyurethane in your
adsorption/elution calculations?
Authors: We believe the observed roughness on surfaces of derivatized material is a drying artifact, one
which may reflect the sites of primary "nucleation" of
the acrylamide. We currently do not know of a way to
calculate precisely the surface area of the modified
surfaces.

J.A. Chinn: Frautschi et al. (1987, personal communication) report enhanced albumin adsorption from buffer
to alkylated polyurethanes, and subsequent low elutability after incubation with SDS. They attribute high retention to strong ligand (alkyl residue)-receptor (albumin)
interaction with native (not denatured) albumin. Further, Munro et al. (1983) propose that adsorbed protein
denatures, then desorbs. Subsequently, a native albumin
molecule adsorbs to the freed alkyl residue. In contrast,
Bohnert and Horbett (1986) interpret low elutability of
adsorbed protein as denaturation. Which adsorption/elution mechanism is most consistent with your data?
Authors: We would agree with Bohnert and Horbett
(1986) that low elutability suggests surface denaturation.
Such avid surface association does not indicate strong ligand-receptor interaction, particularly where low elutability extends to a denaturing agent such as SDS.

].A. Chinn: Protein adsorption is highly temperature
and medium composition dependent. Can you extrapolate your results to physiological conditions, i.e.,
adsorption from whole blood at 37°C?
Authors: We cannot extrapolate our room temperature
protein binding studies to whole blood at 37°C, however, our blood loop results which were performed at
37°C did provide favorable results.
J.A. Chinn: Does human serum albumin (HSA) absorb
into the dextran matrix?
Authors: It is possible that some albumin may absorb
into the dextran matrix.

J.A. Chinn: Sefton (1993) reports that hydrogel surfaces consume platelets, though few platelets are observed adherent to the surface. Does dextran act as a
hydrogel in your system? What does your data in Table
I and Figure 4A indicate about non-adherent platelets?
Authors: We agree that some hydrogel surfaces can
consume platelets, but we disagree with the statement
that all hydrogel surfaces consume platelets. In fact, we
recently have reported on a sulphonated hydrogel surface
which appeared not to consume platelets during a blood

J.A. Chinn: You conclude that the increase in HSA
binding observed with modified polyurethane is due to
ligand-receptor interaction between the immobilized dye
and the protein. How does your data indicate ligandreceptor interaction rather than non-specific absorption
and adsorption, followed by non-specific elution?
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loop experiment (Keogh et al., 1996).

Additional References

J.A. Chinn: Does low bacterial adherence indicated in
Figure 7 represent a kinetic or an equilibrium effect?
Authors: We are not sure if the observed decrease in
bacterial adherence is attributable to a kinetic or an
equilibrium effect, but suspect the latter.

Keogh JR, WolfMF, Overend ME, Tang L, Eaton
JW (1996) Biocompatibility of sulphonated polyurethane
surfaces. Biomaterials 17: 1987-1994.
Munro MS, Eberhart RC, Maki NJ, Brink BE, Fry
WJ (1983) Thromboresistant alkyl derivatized polyurethanes. ASAIO (Am Soc Artif Intern Organs) J 6: 6573.
Sefton MV (1993) The good, the bad and the
obvious: 1993 Clemson Award for Basic Research keynote lecture. Biornaterials 14: 1127-1134.

R.C. Eberhart: When surfaces are exposed to blood,
plasma, or protein solution, non-specific binding takes
place, i.e., binding not associated with the specific
interaction between the ligand and the protein. Albumin
and other proteins may have some affinity for dextran
(Birkenmeier, 1984, personal communication). Therefore, there may have been some degree of the albumin
binding and retention due to non-specific association
with the dextran and not the cibacron blue. Although
the results of this paper are impressive, perhaps an
instructive control surface would have been unmodified
dextran.
Authors: We have measured albumin binding to dextran-derivatized surfaces (i.e., lacking the final cibacron
blue modification) and found some binding. This binding does not show ligand specificity (i .e., selectivity for
albumin) but is reversible.
R.C. Eberhart: Immersing the sample into a protein
solution is not a very good technique for protein adsorption studies as the air/water interface is known to denature protein. Therefore, as you lower your sample into
the solution, you are passing it through a layer of denatured protein which may or may not still have the cibacron blue binding site intact. Therefore, as in Langmuir-Blodgett films, a film of denatured protein may be
physically attached to your surface by this process independent of any cibacron blue specific binding. Therefore, in the future, I would suggest modifying your
method of protein binding assays so that the adsorbed
proteins do not have opportunity to denature and your
surfaces have a chance to become fully hydrated prior to
protein exposure. Based on this, do you believe that the
protein binding results presented here are indicative of
what might be seen clinically if your surface were to be
used in cardiopulmonary bypass tubing, for example?
Authors: Yes, we believe our protein binding results
would be indicative of what might be seen clinically in
cardiopulmonary bypass tubing. The main thrust of our
binding studies was to investigate the reversible binding
of the proteins under study. The results with albumin
would, if anything, have been made less impressive if
we had been accidentally adsorbing a layer of pre-denatured albumin. But we agree that there are better ways
to do these sorts of protein binding studies.
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